Professor
Wayne State University

1. Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical Outcomes for Patients with Bacteremia Caused by Vancomycin-Resistant Enterococcus in a Level 1 Trauma Center. Clinical Infectious Diseases 2002;34:922-929
2. Mercier R-C, Stumpo C, Rybak MJ. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, Oritivancin (LY333328) against Staphylococcus aureus and Enterococcus faecium. J Antimicrob Chemother 2002; 50:19-24
3. Allen GP, Cha R, Rybak MJ. In Vitro activities of quinupristin-dalfoprostin and cefepime, alone and in combination with various antimicrobials against multidrug-resistant Staphylococci and Enterococci in an In Vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy 2002; 46(8):2606-2612.
4. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with gram-negative infections. J. Antimicrob Chemother 2002;50:425-428.
5. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infectiouns caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surgical Infections 2003; 4(1):57-70.